Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2B Multicenter, Randomized, Double-Blind, Comparative Trial Of UK-453,061, In Combination With Tenofovir Df And Emtricitabine Versus Efavirenz In Combination With Tenofovir DF And Emtricitabine For The Treatment Of Antiretroviral-Naive HIV-1 Infected Subjects

NCT00824421 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00824421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00824421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2B Multicenter, Randomized, Double-Blind, Comparative Trial Of UK-453,061, In Combination With Tenofovir Df And Emtricitabine Versus Efavirenz In Combination With Tenofovir DF And Emtricitabine For The Treatment Of Antiretroviral-Naive HIV-1 Infected Subjects
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2009
Completion date
October 31, 2011
Enrollment
195 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1